[S02DA03, antipyrine, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Antipyrine.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ergoloid mesylate.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Sulindac is combined with Ergoloid mesylate.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sulpiride.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sulthiame.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Azapropazone.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Ergoloid mesylate.]
[R03CC03, terbutaline, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Terbutaline.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Ergoloid mesylate.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be decreased when Apomorphine is combined with Ergoloid mesylate.]
[L04AX02, thalidomide, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thiethylperazine.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Thiopental is combined with Ergoloid mesylate.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thiothixene.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Moxisylyte.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tiapride.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tilidine.]
[S01ED01, timolol, Timolol may increase the vasoconstricting activities of Ergoloid mesylate.]
[M02AX02, tolazoline, Ergoloid mesylate may decrease the antihypertensive activities of Tolazoline.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Tolmetin is combined with Ergoloid mesylate.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Ergoloid mesylate is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ergoloid mesylate.]
[N06AX05, trazodone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Ergoloid mesylate.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Ergoloid mesylate.]
[C03AA06, trichlormethiazide, Ergoloid mesylate may decrease the antihypertensive activities of Trichlormethiazide.]
[A03AB12, mepenzolate, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Trifluoperazine.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Trifluperidol.]
[N05AA05, triflupromazine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Ergoloid mesylate.]
[C02BA01, trimethaphan, Ergoloid mesylate may decrease the antihypertensive activities of Trimethaphan.]
[N06AA06, trimipramine, The risk or severity of adverse effects can be increased when Trimipramine is combined with Ergoloid mesylate.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Ergoloid mesylate.]
[A03BB01, butylscopolamine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The serum concentration of Ergoloid mesylate can be increased when it is combined with Troleandomycin.]
[N06AX24, vilazodone, Ergoloid mesylate may increase the vasoconstricting activities of Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Ergoloid mesylate.]
[C09CA09, azilsartan medoxomil, Ergoloid mesylate may decrease the antihypertensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tubocurarine.]
[A10BH05, linagliptin, The metabolism of Ergoloid mesylate can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The risk or severity of adverse effects can be increased when Boceprevir is combined with Ergoloid mesylate.]
[J05AP02, telaprevir, The serum concentration of Ergoloid mesylate can be increased when it is combined with Telaprevir.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ezogabine.]
[R03AC18, indacaterol, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Indacaterol.]
[C08DA01, verapamil, The metabolism of Ergoloid mesylate can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Ergoloid mesylate can be decreased when combined with Viloxazine.]
[C04AX07, vincamine, Ergoloid mesylate may decrease the antihypertensive activities of Vincamine.]
[B01AA03, warfarin, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Warfarin.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Xenon.]
[C03BA10, xipamide, Ergoloid mesylate may decrease the antihypertensive activities of Xipamide.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Zuclopenthixol.]
[J05AE02, indinavir, The serum concentration of Ergoloid mesylate can be increased when it is combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Levetiracetam.]
[L01ED01, crizotinib, The metabolism of Ergoloid mesylate can be decreased when combined with Crizotinib.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ziprasidone.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Ergoloid mesylate.]
[G04BD07, tolterodine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[C07AB03, atenolol, Atenolol may increase the vasoconstricting activities of Ergoloid mesylate.]
[J02AC03, voriconazole, The serum concentration of Ergoloid mesylate can be increased when it is combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Atracurium.]
[S01FA01, atropine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[G04BE10, avanafil, Ergoloid mesylate may increase the hypotensive activities of Avanafil.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Ergoloid mesylate.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Lorcaserin is combined with Ergoloid mesylate.]
[G04BD12, mirabegron, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Mirabegron.]
[V03AX03, cobicistat, The serum concentration of Ergoloid mesylate can be increased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The serum concentration of Ergoloid mesylate can be increased when it is combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Ergoloid mesylate can be decreased when it is combined with Enzalutamide.]
[C01CA18, octopamine, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Octopamine.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Barbital.]
[J05AE04, nelfinavir, The serum concentration of Ergoloid mesylate can be increased when it is combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Ergoloid mesylate.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Rasagiline.]
[C08CA13, lercanidipine, Ergoloid mesylate may decrease the antihypertensive activities of Lercanidipine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Ergoloid mesylate.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ergoloid mesylate.]
[N02CC03, zolmitriptan, Ergoloid mesylate may increase the vasoconstricting activities of Zolmitriptan.]
[R06AC06, thonzylamine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Diethyl ether.]
[C03AA01, bendroflumethiazide, Ergoloid mesylate may decrease the antihypertensive activities of Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pomalidomide.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Benperidol.]
[A06AX06, tegaserod, The risk or severity of serotonin syndrome can be increased when Ergoloid mesylate is combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Benzocaine.]
[M01AH01, celecoxib, The risk or severity of hypertension can be increased when Celecoxib is combined with Ergoloid mesylate.]
[N02CC02, naratriptan, Ergoloid mesylate may increase the vasoconstricting activities of Naratriptan.]
[L04AA18, everolimus, The serum concentration of Ergoloid mesylate can be increased when it is combined with Everolimus.]
[N04AC01, benztropine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Ergoloid mesylate can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Benzydamine.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Levomilnacipran.]
[C08EA02, bepridil, Ergoloid mesylate may decrease the antihypertensive activities of Bepridil.]
[C02KX05, riociguat, Ergoloid mesylate may decrease the antihypertensive activities of Riociguat.]
[C02KX04, macitentan, Ergoloid mesylate may decrease the antihypertensive activities of Macitentan.]
[N06AX26, vortioxetine, Ergoloid mesylate may increase the vasoconstricting activities of Vortioxetine.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Ergoloid mesylate can be decreased when combined with Simeprevir.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Vigabatrin.]
[C01CA27, droxidopa, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Droxidopa.]
[C07AB04, acebutolol, Acebutolol may increase the vasoconstricting activities of Ergoloid mesylate.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Ergoloid mesylate can be increased when combined with Metreleptin.]
[S01ED02, betaxolol, Betaxolol may increase the vasoconstricting activities of Ergoloid mesylate.]
[C02CC01, bethanidine, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Bethanidine.]
[A03BA03, hyoscyamine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Acenocoumarol.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Alfaxalone.]
[R03AC19, olodaterol, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Olodaterol.]
[D11AA01, glycopyrronium, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Acepromazine.]
[N04AA02, biperiden, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Dicoumarol.]
[N06AX11, mirtazapine, Ergoloid mesylate may increase the serotonergic activities of Mirtazapine.]
[A03AA09, difemerine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tioclomarol.]
[A07DA06, eluxadoline, The risk or severity of serotonin syndrome can be increased when Ergoloid mesylate is combined with Eluxadoline.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be decreased when Ergoloid mesylate is combined with Brexpiprazole.]
[G02CX02, flibanserin, Ergoloid mesylate may increase the vasoconstricting activities of Flibanserin.]
[N05AX15, cariprazine, Ergoloid mesylate may increase the vasoconstricting activities of Cariprazine.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Ergoloid mesylate.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Acetophenazine.]
[J02AC05, isavuconazole, The metabolism of Ergoloid mesylate can be decreased when combined with Isavuconazole.]
[B01AC27, selexipag, Ergoloid mesylate may decrease the antihypertensive activities of Selexipag.]
[G04CA01, alfuzosin, Ergoloid mesylate may increase the hypotensive activities of Alfuzosin.]
[A03FA05, alizapride, The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Alizapride.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Aprobarbital.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Alminoprofen.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Brivaracetam.]
[L01XX52, venetoclax, The metabolism of Ergoloid mesylate can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Bromazepam.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be decreased when Ergoloid mesylate is combined with Bromocriptine.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ergoloid mesylate.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Amineptine.]
[C08CA01, amlodipine, Ergoloid mesylate may decrease the antihypertensive activities of Amlodipine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Aniracetam.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Ergoloid mesylate.]
[C07AA19, bupranolol, Bupranolol may increase the vasoconstricting activities of Ergoloid mesylate.]
[N07BC01, buprenorphine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Ergoloid mesylate.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Ergoloid mesylate.]
[S01GX07, azelastine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[S01AA26, azithromycin, The serum concentration of Ergoloid mesylate can be increased when it is combined with Azithromycin.]
[L01EF02, ribociclib, The serum concentration of Ergoloid mesylate can be increased when it is combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Balsalazide is combined with Ergoloid mesylate.]
[R03CC12, bambuterol, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Bambuterol.]
[N02BF02, pregabalin, The therapeutic efficacy of Ergoloid mesylate can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Beclamide.]
[C09AA07, benazepril, Ergoloid mesylate may decrease the antihypertensive activities of Benazepril.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ergoloid mesylate.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Ergoloid mesylate.]
[J05AE09, tipranavir, The serum concentration of Ergoloid mesylate can be increased when it is combined with Tipranavir.]
[L01EX10, midostaurin, The serum concentration of Ergoloid mesylate can be increased when it is combined with Midostaurin.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Safinamide.]
[C07AB07, bisoprolol, Bisoprolol may increase the vasoconstricting activities of Ergoloid mesylate.]
[R03AC17, bitolterol, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Bitolterol.]
[J05AG03, efavirenz, The serum concentration of Ergoloid mesylate can be increased when it is combined with Efavirenz.]
[C07AA17, bopindolol, Bopindolol may increase the vasoconstricting activities of Ergoloid mesylate.]
[N04AA11, bornaprine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[A03FA04, bromopride, The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Bromopride.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Brotizolam.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Bumadizone.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Butobarbital.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Butriptyline.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Vinylbital.]
[C09AA01, captopril, Ergoloid mesylate may decrease the antihypertensive activities of Captopril.]
[L02BB05, apalutamide, The metabolism of Ergoloid mesylate can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Ergoloid mesylate can be increased when combined with Carbamazepine.]
[A03AA03, camylofine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Ergoloid mesylate.]
[C07AG02, carvedilol, Carvedilol may increase the vasoconstricting activities of Ergoloid mesylate.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Ergoloid mesylate.]
[C07AB08, celiprolol, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Celiprolol.]
[L01XX62, ivosidenib, The metabolism of Ergoloid mesylate can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Ergoloid mesylate can be decreased when combined with Stiripentol.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Ergoloid mesylate.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Lornoxicam.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Ergoloid mesylate.]
[R03BB08, revefenacin, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01EX13, gilteritinib, The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Gilteritinib.]
[C09AA08, cilazapril, Ergoloid mesylate may decrease the antihypertensive activities of Cilazapril.]
[A03FA08, cinitapride, Ergoloid mesylate may increase the vasoconstricting activities of Cinitapride.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Ergoloid mesylate.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Siponimod.]
[J01FA09, clarithromycin, The serum concentration of Ergoloid mesylate can be increased when it is combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Ergoloid mesylate.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Brexanolone.]
[A03FA06, clebopride, The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Clebopride.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Ergoloid mesylate.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Cloxazolam.]
[C09CA06, candesartan, Ergoloid mesylate may decrease the antihypertensive activities of Candesartan.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Cyamemazine.]
[C03BX03, cicletanine, Ergoloid mesylate may decrease the antihypertensive activities of Cicletanine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Ergoloid mesylate.]
[N07XX11, pitolisant, The serum concentration of Ergoloid mesylate can be decreased when it is combined with Pitolisant.]
[C03AA09, cyclothiazide, Ergoloid mesylate may decrease the antihypertensive activities of Cyclothiazide.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Yohimbine.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Ergoloid mesylate.]
[N03AX25, cenobamate, The serum concentration of Ergoloid mesylate can be decreased when it is combined with Cenobamate.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ergoloid mesylate.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Dezocine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lumateperone.]
[J05AE05, amprenavir, The serum concentration of Ergoloid mesylate can be increased when it is combined with Amprenavir.]
[N02CC07, frovatriptan, Ergoloid mesylate may increase the vasoconstricting activities of Frovatriptan.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Dutasteride.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Dichloralphenazone.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Dihydrocodeine.]
[N02CC06, eletriptan, Ergoloid mesylate may increase the vasoconstricting activities of Eletriptan.]
[M01AH02, rofecoxib, The risk or severity of hypertension can be increased when Rofecoxib is combined with Ergoloid mesylate.]
[C01BD07, dronedarone, The metabolism of Ergoloid mesylate can be decreased when combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Valpromide.]
[J01FA13, dirithromycin, The serum concentration of Ergoloid mesylate can be increased when it is combined with Dirithromycin.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ergoloid mesylate.]
[C02AA06, methoserpidine, Ergoloid mesylate may decrease the antihypertensive activities of Methoserpidine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Ergoloid mesylate.]
[A03AA08, dihexyverine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[C01CA14, dopexamine, The risk or severity of adverse effects can be decreased when Ergoloid mesylate is combined with Dopexamine.]
[G04BD09, trospium, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Droxicam.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Ergoloid mesylate.]
[C08CA17, levamlodipine, Ergoloid mesylate may decrease the antihypertensive activities of Levamlodipine.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Remimazolam.]
[L04AC19, satralizumab, The serum concentration of Ergoloid mesylate can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Ergoloid mesylate is combined with Oliceridine.]
[C03AA04, chlorothiazide, Ergoloid mesylate may decrease the antihypertensive activities of Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.]
[N05AF03, chlorprothixene, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[C03BA04, chlorthalidone, Ergoloid mesylate may decrease the antihypertensive activities of Chlorthalidone.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ergoloid mesylate.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Etifoxine.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Ethenzamide.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ethyl loflazepate.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Etodolac is combined with Ergoloid mesylate.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Ergoloid mesylate can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The serum concentration of Ergoloid mesylate can be increased when it is combined with Lonafarnib.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Naxitamab.]
[P03AX07, abametapir, The serum concentration of Ergoloid mesylate can be increased when it is combined with Abametapir.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Felbamate is combined with Ergoloid mesylate.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Fenbufen.]
[C01CA19, fenoldopam, The risk or severity of adverse effects can be decreased when Fenoldopam is combined with Ergoloid mesylate.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Finasteride.]
[R03CC15, formoterol, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Formoterol.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Trichloroethylene.]
[H04AA02, dasiglucagon, Ergoloid mesylate may decrease the antihypertensive activities of Dasiglucagon.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Ergoloid mesylate.]
[L01XX73, sotorasib, The serum concentration of Ergoloid mesylate can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Ergoloid mesylate can be decreased when combined with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Citalopram.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Ergoloid mesylate.]
[R03CC13, clenbuterol, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Clenbuterol.]
[J01FF01, clindamycin, The serum concentration of Ergoloid mesylate can be increased when it is combined with Clindamycin.]
[N06AX25, St. John's wort extract, The metabolism of Ergoloid mesylate can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Ergoloid mesylate.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ergoloid mesylate.]
[N06AA04, clomipramine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Clomipramine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Ergoloid mesylate.]
[C01EB24, mavacamten, The serum concentration of Ergoloid mesylate can be decreased when it is combined with Mavacamten.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Ondansetron is combined with Ergoloid mesylate.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Ergoloid mesylate.]
[N05AH02, clozapine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Clozapine.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Ergoloid mesylate.]
[H01AC08, somatrogon, The metabolism of Ergoloid mesylate can be increased when combined with Somatrogon.]
[S02DA02, cocaine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, Ergoloid mesylate may increase the sedative activities of Metyrosine.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Ergoloid mesylate.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Ergoloid mesylate.]
[A03AB10, hexocyclium, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ifenprodil.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Imidazole salicylate.]
[J01FA15, telithromycin, The serum concentration of Ergoloid mesylate can be increased when it is combined with Telithromycin.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Ergoloid mesylate.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Valdecoxib is combined with Ergoloid mesylate.]
[A03AX10, isometheptene, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Isometheptene.]
[N02CC05, almotriptan, Ergoloid mesylate may increase the vasoconstricting activities of Almotriptan.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Parecoxib.]
[J02AC02, itraconazole, The serum concentration of Ergoloid mesylate can be increased when it is combined with Itraconazole.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ketazolam.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Kebuzone.]
[J02AC04, posaconazole, The serum concentration of Ergoloid mesylate can be increased when it is combined with Posaconazole.]
[C08CA09, lacidipine, Ergoloid mesylate may decrease the antihypertensive activities of Lacidipine.]
[N03AX09, lamotrigine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[N07BC04, lofexidine, The therapeutic efficacy of Ergoloid mesylate can be increased when used in combination with Lofexidine.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Lonazolac.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lormetazepam.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Loxoprofen.]
[C09AA03, lisinopril, Ergoloid mesylate may decrease the antihypertensive activities of Lisinopril.]
[C08CA11, manidipine, Ergoloid mesylate may decrease the antihypertensive activities of Manidipine.]
[A03AA04, mebeverine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Medifoxamine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Mefenorex.]
[C07AA14, mepindolol, Mepindolol may increase the vasoconstricting activities of Ergoloid mesylate.]
[N04AA03, methixene, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R03CB02, methoxyphenamine, The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Cyclobarbital.]
[C03DA04, eplerenone, Ergoloid mesylate may decrease the antihypertensive activities of Eplerenone.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Melperone.]
[C03AA07, cyclopenthiazide, Ergoloid mesylate may decrease the antihypertensive activities of Cyclopenthiazide.]
[J01FA03, midecamycin, The serum concentration of Ergoloid mesylate can be increased when it is combined with Midecamycin.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Minaprine is combined with Ergoloid mesylate.]
[S01XA18, cyclosporine, The metabolism of Ergoloid mesylate can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Moclobemide.]
[R06AX02, cyproheptadine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, Ergoloid mesylate may decrease the antihypertensive activities of Moexipril.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Morniflumate.]
[C03XA02, conivaptan, The serum concentration of Ergoloid mesylate can be increased when it is combined with Conivaptan.]
[C02AC05, moxonidine, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Moxonidine.]
[M01AH05, etoricoxib, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Etoricoxib.]
[G03XA01, danazol, The serum concentration of Ergoloid mesylate can be increased when it is combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Dantrolene.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Deanol.]
[C02CC04, debrisoquin, Ergoloid mesylate may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Ergoloid mesylate.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Nabumetone is combined with Ergoloid mesylate.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Nordazepam.]
[C07AB12, nebivolol, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Nebivolol.]
[N06AX06, nefazodone, The serum concentration of Ergoloid mesylate can be increased when it is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Niaprazine.]
[C01DX16, nicorandil, Ergoloid mesylate may decrease the antihypertensive activities of Nicorandil.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Ergoloid mesylate.]
[C01CA23, theodrenaline, Ergoloid mesylate may decrease the hypertensive activities of Theodrenaline.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Ergoloid mesylate.]
[C01CA05, norfenefrine, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Norfenefrine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Ergoloid mesylate is combined with Escitalopram.]
[G04BD08, solifenacin, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Olsalazine.]
[N06AA01, desipramine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Ergoloid mesylate.]
[C09XA02, aliskiren, Ergoloid mesylate may decrease the antihypertensive activities of Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Oxaprozin is combined with Ergoloid mesylate.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Ergoloid mesylate.]
[S03BA01, dexamethasone, The metabolism of Ergoloid mesylate can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Oxiracetam.]
[N04AA08, dexetimide, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Ergoloid mesylate is combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Amphetamine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Ergoloid mesylate.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Ergoloid mesylate.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Paroxetine.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Diamorphine.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Ergoloid mesylate.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Phenacemide.]
[V03AH01, diazoxide, Ergoloid mesylate may decrease the antihypertensive activities of Diazoxide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Ergoloid mesylate.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Ergoloid mesylate.]
[S01BC03, diclofenac, The risk or severity of hypertension can be increased when Diclofenac is combined with Ergoloid mesylate.]
[A03AA07, dicyclomine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[C02DG01, pinacidil, Ergoloid mesylate may decrease the antihypertensive activities of Pinacidil.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pipamperone.]
[A03AB14, pipenzolate, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01DC04, ixabepilone, The serum concentration of Ergoloid mesylate can be increased when it is combined with Ixabepilone.]
[R03CC07, pirbuterol, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Pirbuterol.]
[A08AA03, diethylpropion, The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Diethylpropion.]
[C08CA03, isradipine, The metabolism of Ergoloid mesylate can be decreased when combined with Isradipine.]
[A03AB11, poldine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Diflunisal is combined with Ergoloid mesylate.]
[C02DB01, dihydralazine, Ergoloid mesylate may decrease the antihypertensive activities of Dihydralazine.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be decreased when Dihydroergotamine is combined with Ergoloid mesylate.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ergoloid mesylate.]
[J05AE08, atazanavir, The serum concentration of Ergoloid mesylate can be increased when it is combined with Atazanavir.]
[B01AC21, treprostinil, Ergoloid mesylate may decrease the antihypertensive activities of Treprostinil.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Ergoloid mesylate can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ergoloid mesylate.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pridinol.]
[R06AB03, dimethindene, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Procaterol.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Ergoloid mesylate.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Proglumetacin.]
[R06AA02, diphenhydramine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Quazepam.]
[C09AA06, quinapril, Ergoloid mesylate may decrease the antihypertensive activities of Quinapril.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Cisapride is combined with Ergoloid mesylate.]
[C09AA05, ramipril, Ergoloid mesylate may decrease the antihypertensive activities of Ramipril.]
[S01XA23, sirolimus, The serum concentration of Ergoloid mesylate can be increased when it is combined with Sirolimus.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Remoxipride.]
[R03CC14, reproterol, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Reproterol.]
[C01BA03, disopyramide, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S02AA12, rifamycin SV, The metabolism of Ergoloid mesylate can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Ergoloid mesylate can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Ergoloid mesylate.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ergoloid mesylate.]
[A04AD12, aprepitant, The metabolism of Ergoloid mesylate can be decreased when combined with Aprepitant.]
[G04BE08, tadalafil, Ergoloid mesylate may decrease the antihypertensive activities of Tadalafil.]
[S01BC05, ketorolac, The risk or severity of hypertension can be increased when Ketorolac is combined with Ergoloid mesylate.]
[C02KX02, ambrisentan, Ergoloid mesylate may decrease the antihypertensive activities of Ambrisentan.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Salsalate.]
[R03AC12, salmeterol, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Salmeterol.]
[C01CA07, dobutamine, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Dobutamine.]
[A03FA03, domperidone, The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Domperidone.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Dopamine is combined with Ergoloid mesylate.]
[N06AA16, dothiepin, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Ergoloid mesylate.]
[N06AA12, doxepin, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ergoloid mesylate.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ergoloid mesylate.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sibutramine.]
[C09AA11, spirapril, Ergoloid mesylate may decrease the antihypertensive activities of Spirapril.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sultopride.]
[N02CC01, sumatriptan, Ergoloid mesylate may increase the vasoconstricting activities of Sumatriptan.]
[G01AF05, econazole, The serum concentration of Ergoloid mesylate can be increased when it is combined with Econazole.]
[C07AB13, talinolol, Talinolol may increase the vasoconstricting activities of Ergoloid mesylate.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Tenoxicam is combined with Ergoloid mesylate.]
[G04CA03, terazosin, Ergoloid mesylate may decrease the antihypertensive activities of Terazosin.]
[C07AA16, tertatolol, Tertatolol may increase the vasoconstricting activities of Ergoloid mesylate.]
[S01GA02, tetrahydrozoline, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Tetryzoline.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thiopropazate.]
[G04BD01, emepronium, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tianeptine.]
[C09AA02, enalapril, Ergoloid mesylate may decrease the antihypertensive activities of Enalapril.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tofisopam.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Toloxatone.]
[N06BA09, atomoxetine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Ergoloid mesylate.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Ergoloid mesylate.]
[C03CA04, torsemide, Ergoloid mesylate may decrease the antihypertensive activities of Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Tramazoline.]
[C09AA10, trandolapril, Ergoloid mesylate may decrease the antihypertensive activities of Trandolapril.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Triclofos.]
[A03AB08, tridihexethyl, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Ergoloid mesylate.]
[N04AA12, tropatepine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[R03CC11, tulobuterol, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Tulobuterol.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Ergoloid mesylate.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Urapidil.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Veralipride.]
[S01FB02, ephedrine, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Ephedrine.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Ergoloid mesylate.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Ergoloid mesylate is combined with Venlafaxine.]
[C01CX07, xamoterol, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Xamoterol.]
[S01GA03, xylometazoline, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Xylometazoline.]
[C08CA12, mepirodipine, The metabolism of Ergoloid mesylate can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Epinephrine.]
[C09AA15, zofenopril, Ergoloid mesylate may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Zonisamide is combined with Ergoloid mesylate.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Zotepine.]
[C02AC02, guanfacine, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Guanfacine.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Moricizine.]
[G02AB03, ergonovine, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Ergometrine.]
[S01AA13, fusidic acid, The metabolism of Ergoloid mesylate can be decreased when combined with Fusidic acid.]
[N07XX04, sodium oxybate, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[M01AG01, mefenamic acid, The risk or severity of hypertension can be increased when Mefenamic acid is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The serum concentration of Ergoloid mesylate can be increased when it is combined with Ergotamine.]
[S01AA17, erythromycin, Erythromycin may increase the vasoconstricting activities of Ergoloid mesylate.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Estazolam.]
[C01CA15, gepefrine, The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ergoloid mesylate.]
[N04AA05, profenamine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Ergoloid mesylate.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Ergoloid mesylate.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Meloxicam is combined with Ergoloid mesylate.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ethylmorphine.]
[C01CA01, etilefrine, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Etilefrine.]
[N01AX07, etomidate, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Etomidate.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sertindole.]
[R06AX12, terfenadine, The serum concentration of Ergoloid mesylate can be increased when it is combined with Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Bupropion.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fluvoxamine.]
[C08CA02, felodipine, Ergoloid mesylate may decrease the antihypertensive activities of Felodipine.]
[N03AX26, fenfluramine, The risk or severity of serotonin syndrome can be increased when Ergoloid mesylate is combined with Fenfluramine.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Fenoprofen is combined with Ergoloid mesylate.]
[R03CC04, fenoterol, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Fenoterol.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Fentanyl is combined with Ergoloid mesylate.]
[R03CC02, albuterol, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Salbutamol.]
[G04BD02, flavoxate, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Ergoloid mesylate can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Flunitrazepam.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Melitracen.]
[V03AZ01, ethanol, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[N06AB03, fluoxetine, The risk or severity of serotonin syndrome can be increased when Ergoloid mesylate is combined with Fluoxetine.]
[N05AF01, flupenthixol, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fluphenazine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Ergoloid mesylate.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Flurbiprofen is combined with Ergoloid mesylate.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fluspirilene.]
[N06BX17, adrafinil, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Adrafinil.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Furazolidone is combined with Ergoloid mesylate.]
[J05AE10, darunavir, The serum concentration of Ergoloid mesylate can be increased when it is combined with Darunavir.]
[C03CA01, furosemide, Ergoloid mesylate may decrease the antihypertensive activities of Furosemide.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Ergoloid mesylate is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Amisulpride.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Gallamine.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Bifemelane.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be decreased when Cabergoline is combined with Ergoloid mesylate.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Ergoloid mesylate.]
[N05CM18, dexmedetomidine, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Dexmedetomidine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Glutethimide.]
[C05AE01, nitroglycerin, The bioavailability of Ergoloid mesylate can be increased when combined with Nitroglycerin.]
[C02CA04, doxazosin, Ergoloid mesylate may decrease the antihypertensive activities of Doxazosin.]
[C07AB09, esmolol, Esmolol may increase the vasoconstricting activities of Ergoloid mesylate.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fluindione.]
[C09AA09, fosinopril, Ergoloid mesylate may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Ergoloid mesylate may decrease the antihypertensive activities of Guanethidine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Ergoloid mesylate.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Halothane.]
[N05AH04, quetiapine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Allobarbital.]
[C09CA01, losartan, Ergoloid mesylate may decrease the antihypertensive activities of Losartan.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Ergoloid mesylate.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Hexobarbital.]
[R03CC05, hexoprenaline, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Hexoprenaline.]
[C08CA10, nilvadipine, The metabolism of Ergoloid mesylate can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Nimesulide.]
[C09AA04, perindopril, Ergoloid mesylate may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Ergoloid mesylate may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, Ergoloid mesylate may decrease the antihypertensive activities of Hydrochlorothiazide.]
[R05DA03, hydrocodone, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, Ergoloid mesylate may decrease the antihypertensive activities of Hydroflumethiazide.]
[G04BD06, propiverine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Prothipendyl.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ergoloid mesylate.]
[C02AC06, rilmenidine, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Rilmenidine.]
[R02AX02, ibuprofen, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Ibuprofen.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Ergoloid mesylate.]
[N06AA02, imipramine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Imipramine.]
[M03BX02, tizanidine, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Tizanidine.]
[C03BA11, indapamide, Ergoloid mesylate may decrease the antihypertensive activities of Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypertension can be increased when Indomethacin is combined with Ergoloid mesylate.]
[C02CA02, indoramin, Ergoloid mesylate may decrease the antihypertensive activities of Indoramin.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Milnacipran.]
[A03AA30, piperidolate, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Articaine.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Ergoloid mesylate.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Ergoloid mesylate.]
[R06AE01, buclizine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C07AA01, alprenolol, Alprenolol may increase the vasoconstricting activities of Ergoloid mesylate.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Iproniazid.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Isocarboxazid.]
[R03CC06, isoetharine, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Isoetharine.]
[C09AA16, imidapril, Ergoloid mesylate may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Ergoloid mesylate.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Ergoloid mesylate.]
[J04AC01, isoniazid, The metabolism of Ergoloid mesylate can be decreased when combined with Isoniazid.]
[R03CB01, isoproterenol, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Isoprenaline.]
[C04AA01, isoxsuprine, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Isoxsuprine.]
[J01FA07, josamycin, The serum concentration of Ergoloid mesylate can be increased when it is combined with Josamycin.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Ergoloid mesylate.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ketanserin.]
[J02AB02, ketoconazole, The serum concentration of Ergoloid mesylate can be increased when it is combined with Ketoconazole.]
[N05AH03, olanzapine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Ketoprofen is combined with Ergoloid mesylate.]
[C01CA22, arbutamine, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Arbutamine.]
[N04BC09, rotigotine, Ergoloid mesylate may increase the sedative activities of Rotigotine.]
[C07AG01, labetalol, Labetalol may increase the vasoconstricting activities of Ergoloid mesylate.]
[N04BB01, amantadine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Ergoloid mesylate.]
[C02AA05, deserpidine, Ergoloid mesylate may decrease the antihypertensive activities of Deserpidine.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lacosamide.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Lidocaine.]
[N02CA07, lisuride, The risk or severity of adverse effects can be decreased when Lisuride is combined with Ergoloid mesylate.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lofepramine.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Ergoloid mesylate.]
[C10AA02, lovastatin, The metabolism of Ergoloid mesylate can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Loxapine.]
[L01EG01, temsirolimus, The serum concentration of Ergoloid mesylate can be increased when it is combined with Temsirolimus.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Ergoloid mesylate can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The serum concentration of Ergoloid mesylate can be increased when it is combined with Nilotinib.]
[N06AA21, maprotiline, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Ergoloid mesylate.]
[C02BB01, mecamylamine, Ergoloid mesylate may decrease the antihypertensive activities of Mecamylamine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Ergoloid mesylate.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Ergoloid mesylate.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Medazepam.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Melatonin.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Ergoloid mesylate.]
[C01CA11, mephentermine, The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Ergoloid mesylate.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ergoloid mesylate.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Mepivacaine is combined with Ergoloid mesylate.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Ergoloid mesylate.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Meptazinol.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Paliperidone.]
[C01CA09, metaraminol, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Metaraminol.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Ergoloid mesylate.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Ergoloid mesylate.]
[N06BA03, methamphetamine, The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Metamfetamine.]
[A03AB07, methantheline, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Methaqualone.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Ergoloid mesylate.]
[G02CB05, metergoline, The risk or severity of adverse effects can be decreased when Ergoloid mesylate is combined with Metergoline.]
[H03BB02, methimazole, The serum concentration of Ergoloid mesylate can be increased when it is combined with Methimazole.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Ergoloid mesylate.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Ergoloid mesylate.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Methoxamine.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ergoloid mesylate.]
[C02AB01, methyldopa, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Methyldopa.]
[V04CG05, methylene blue, Ergoloid mesylate may increase the serotonergic activities of Methylene blue.]
[G02AB01, methylergonovine, The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Methylergometrine.]
[N06BA04, methylphenidate, The risk or severity of hypertension can be increased when Methylphenidate is combined with Ergoloid mesylate.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Ergoloid mesylate.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Ergoloid mesylate.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Ergoloid mesylate.]
[C03BA08, metolazone, Ergoloid mesylate may decrease the antihypertensive activities of Metolazone.]
[C07AB02, metoprolol, Metoprolol may increase the vasoconstricting activities of Ergoloid mesylate.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Ergoloid mesylate can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Aminophenazone.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Ergoloid mesylate.]
[C01CA17, midodrine, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Midodrine.]
[G03XB01, mifepristone, The serum concentration of Ergoloid mesylate can be increased when it is combined with Mifepristone.]
[C09CA03, valsartan, Ergoloid mesylate may decrease the antihypertensive activities of Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ergoloid mesylate.]
[D11AX01, minoxidil, Ergoloid mesylate may decrease the antihypertensive activities of Minoxidil.]
[J01FA11, miocamycin, The serum concentration of Ergoloid mesylate can be increased when it is combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Ergoloid mesylate can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Lisdexamfetamine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Molindone.]
[C01BD01, amiodarone, The serum concentration of Ergoloid mesylate can be increased when it is combined with Amiodarone.]
[N06AA09, amitriptyline, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Ergoloid mesylate.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Ergoloid mesylate.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Vecuronium.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Amobarbital.]
[N06AA17, amoxapine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.]
[N03AB05, fosphenytoin, The metabolism of Ergoloid mesylate can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, Nadolol may increase the vasoconstricting activities of Ergoloid mesylate.]
[N04BC04, ropinirole, Ergoloid mesylate may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Ergoloid mesylate.]
[V03AB15, naloxone, The serum concentration of Ergoloid mesylate can be increased when it is combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Ergoloid mesylate.]
[S01GA01, naphazoline, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Naphazoline.]
[N06BA01, amphetamine, The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Amphetamine.]
[M02AA12, naproxen, The risk or severity of hypertension can be increased when Naproxen is combined with Ergoloid mesylate.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Ergoloid mesylate.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Ergoloid mesylate.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Iloperidone.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Desvenlafaxine.]
[C09CA07, telmisartan, Ergoloid mesylate may decrease the antihypertensive activities of Telmisartan.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Nialamide.]
[C08CA04, nicardipine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.]
[C04AE02, nicergoline, The risk or severity of hypertension can be increased when Nicergoline is combined with Ergoloid mesylate.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Niflumic acid.]
[C08CA06, nimodipine, Ergoloid mesylate may decrease the antihypertensive activities of Nimodipine.]
[C08CA07, nisoldipine, Ergoloid mesylate may decrease the antihypertensive activities of Nisoldipine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Nitrazepam.]
[C08CA08, nitrendipine, Ergoloid mesylate may decrease the antihypertensive activities of Nitrendipine.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Ergoloid mesylate.]
[N04BC05, pramipexole, Ergoloid mesylate may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Ergoloid mesylate may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Nomifensine.]
[C01CA03, norepinephrine, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Norepinephrine.]
[C02KX01, bosentan, Ergoloid mesylate may decrease the antihypertensive activities of Bosentan.]
[N06AA10, nortriptyline, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.]
[G02CA02, nylidrin, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Nylidrin.]
[J01FA05, oleandomycin, The serum concentration of Ergoloid mesylate can be increased when it is combined with Oleandomycin.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Opium.]
[R03CB03, metaproterenol, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Orciprenaline.]
[G02CB04, quinagolide, The risk or severity of adverse effects can be decreased when Ergoloid mesylate is combined with Quinagolide.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Ergoloid mesylate.]
[C07AA02, oxprenolol, Oxprenolol may increase the vasoconstricting activities of Ergoloid mesylate.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Ergoloid mesylate.]
[C01DX03, oxyfedrine, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Oxyfedrine.]
[S01GA04, oxymetazoline, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Oxymetazoline.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ergoloid mesylate.]
[M03AC01, pancuronium, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[N05CC05, paraldehyde, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pargyline.]
[G04BD11, fesoterodine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, Penbutolol may increase the vasoconstricting activities of Ergoloid mesylate.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Penfluridol.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Ergoloid mesylate.]
[N05CA01, pentobarbital, The metabolism of Ergoloid mesylate can be increased when combined with Pentobarbital.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be decreased when Ergoloid mesylate is combined with Pergolide.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Perphenazine.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Phenazocine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Phenelzine is combined with Ergoloid mesylate.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Phenindione.]
[N03AA02, phenobarbital, The metabolism of Ergoloid mesylate can be increased when combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, Ergoloid mesylate may decrease the antihypertensive activities of Phenoxybenzamine.]
[B01AA04, phenprocoumon, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Phenprocoumon.]
[A08AA01, phentermine, The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Phentermine.]
[V03AB36, phentolamine, Ergoloid mesylate may decrease the antihypertensive activities of Phentolamine.]
[M02AA01, phenylbutazone, The risk or severity of hypertension can be increased when Phenylbutazone is combined with Ergoloid mesylate.]
[S01GA05, phenylephrine, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Phenylephrine.]
[R01BA01, phenylpropanolamine, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Phenylpropanolamine.]
[N03AB02, phenytoin, The metabolism of Ergoloid mesylate can be increased when combined with Phenytoin.]
[C08CX01, mibefradil, Ergoloid mesylate may decrease the antihypertensive activities of Mibefradil.]
[N05AG02, pimozide, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pimozide.]
[C07AA03, pindolol, Pindolol may increase the vasoconstricting activities of Ergoloid mesylate.]
[J05AE01, saquinavir, The serum concentration of Ergoloid mesylate can be increased when it is combined with Saquinavir.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pipotiazine.]
[C09CA02, eprosartan, Ergoloid mesylate may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N04BC08, piribedil, The risk or severity of adverse effects can be decreased when Ergoloid mesylate is combined with Piribedil.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Piritramide.]
[S01BC06, piroxicam, The risk or severity of hypertension can be increased when Piroxicam is combined with Ergoloid mesylate.]
[N02CX01, pizotyline, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[J05AG02, delavirdine, The serum concentration of Ergoloid mesylate can be increased when it is combined with Delavirdine.]
[C09CA04, irbesartan, Ergoloid mesylate may decrease the antihypertensive activities of Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Proxibarbal.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Alosetron is combined with Ergoloid mesylate.]
[C03AA05, polythiazide, Ergoloid mesylate may decrease the antihypertensive activities of Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Ergoloid mesylate can be increased when it is combined with Ritonavir.]
[C07AB01, practolol, Practolol may increase the vasoconstricting activities of Ergoloid mesylate.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Prazepam.]
[C02CA01, prazosin, Ergoloid mesylate may decrease the antihypertensive activities of Prazosin.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Ergoloid mesylate.]
[P01BA03, primaquine, The metabolism of Ergoloid mesylate can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Ergoloid mesylate can be increased when combined with Primidone.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Procaine is combined with Ergoloid mesylate.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Procarbazine.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Prochlorperazine.]
[N04AA04, procyclidine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[N05AA03, promazine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, Propafenone may increase the vasoconstricting activities of Ergoloid mesylate.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Propanidid.]
[A03AB05, propantheline, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Periciazine.]
[N05CM06, propiomazine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Ergoloid mesylate.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ergoloid mesylate.]
[C07AA05, propranolol, Propranolol may increase the vasoconstricting activities of Ergoloid mesylate.]
[N02CC04, rizatriptan, Ergoloid mesylate may increase the vasoconstricting activities of Rizatriptan.]
[B01AC09, epoprostenol, Ergoloid mesylate may decrease the antihypertensive activities of Epoprostenol.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Ergoloid mesylate.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, The risk or severity of adverse effects can be decreased when Ergoloid mesylate is combined with Aripiprazole.]
[A03AB15, diphemanil, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Ergoloid mesylate.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Mepyramine.]
[C01BA01, quinidine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Quinidine.]
[P01BC01, quinine, The risk or severity of adverse effects can be increased when Quinine is combined with Ergoloid mesylate.]
[C02AA01, rescinnamine, Ergoloid mesylate may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Reserpine.]
[J04AB02, rifampin, The metabolism of Ergoloid mesylate can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Rimiterol.]
[G02CA01, ritodrine, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Ritodrine.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Oxitriptan.]
[J01FA06, roxithromycin, Roxithromycin may increase the vasoconstricting activities of Ergoloid mesylate.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Sulfasalazine is combined with Ergoloid mesylate.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Salicylic acid is combined with Ergoloid mesylate.]
[S01FA02, scopolamine, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Ergoloid mesylate.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Selegiline is combined with Ergoloid mesylate.]
[C07AA07, sotalol, Sotalol may increase the vasoconstricting activities of Ergoloid mesylate.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ergoloid mesylate.]
[C01DA14, isosorbide mononitrate, Ergoloid mesylate may increase the vasodilatory activities of Isosorbide mononitrate.]
[H02CA04, levoketoconazole, The serum concentration of Ergoloid mesylate can be increased when it is combined with Levoketoconazole.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Tiaprofenic acid.]
[R03BB01, ipratropium bromide, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
